Regression of iris neovascularisation secondary to diabetic retinopathy with subconjunctival anti-VEGF therapy

Lancet Diabetes Endocrinol. 2014 Feb;2(2):182. doi: 10.1016/S2213-8587(13)70150-5. Epub 2014 Jan 7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Cataract / complications
  • Cataract / pathology
  • Diabetic Retinopathy / drug therapy*
  • Diabetic Retinopathy / pathology
  • Female
  • Humans
  • Intraocular Pressure
  • Iris / blood supply
  • Iris / pathology
  • Middle Aged
  • Neovascularization, Pathologic / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab